10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 306 filers reported holding 10X GENOMICS INC in Q4 2020. The put-call ratio across all filers is 0.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $206,250 | -83.1% | 5,000 | -77.2% | 0.00% | -82.4% |
| Q2 2023 | $1,222,952 | -2.6% | 21,901 | -2.7% | 0.02% | -5.6% |
| Q1 2023 | $1,255,331 | +74.8% | 22,501 | +14.2% | 0.02% | +63.6% |
| Q4 2022 | $718,159 | +28.0% | 19,708 | 0.0% | 0.01% | +22.2% |
| Q3 2022 | $561,000 | -36.8% | 19,708 | +0.5% | 0.01% | -35.7% |
| Q2 2022 | $888,000 | -31.4% | 19,608 | +15.2% | 0.01% | -17.6% |
| Q1 2022 | $1,295,000 | -42.5% | 17,020 | +12.5% | 0.02% | -39.3% |
| Q4 2021 | $2,253,000 | +10.8% | 15,126 | +8.3% | 0.03% | +3.7% |
| Q3 2021 | $2,033,000 | -25.1% | 13,963 | +0.7% | 0.03% | -22.9% |
| Q2 2021 | $2,715,000 | +35.1% | 13,863 | +24.9% | 0.04% | +25.0% |
| Q1 2021 | $2,009,000 | +372.7% | 11,100 | +270.0% | 0.03% | +366.7% |
| Q4 2020 | $425,000 | +36.2% | 3,000 | +20.0% | 0.01% | +20.0% |
| Q3 2020 | $312,000 | +52.2% | 2,500 | +8.7% | 0.01% | +25.0% |
| Q2 2020 | $205,000 | – | 2,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Venrock Management VI, LLC | 962,309 | $188,439,000 | 95.08% |
| Foresite Capital Management II, LLC | 1,753,528 | $343,376,000 | 92.37% |
| Foresite Capital Management I, LLC | 750,000 | $146,865,000 | 88.53% |
| 12 West Capital Management LP | 1,922,000 | $376,366,000 | 15.78% |
| Financial Consulate Inc. | 141,258 | $27,661,000 | 9.97% |
| FINANCIAL CONSULATE, INC | 141,258 | $27,661,000 | 9.97% |
| Meritech Capital Associates V L.L.C. | 1,793,871 | $351,276,000 | 7.51% |
| Andar Capital Management HK Ltd | 51,000 | $9,987,000 | 6.81% |
| JS Capital Management LLC | 540,589 | $105,858,000 | 5.12% |
| Renaissance Capital LLC | 97,281 | $19,050,000 | 3.01% |